P11.06: Could LARP1 be a driving force in ovarian cancer transformation?
An Coosemans(KU Leuven), Sarah P. Blagden(Churchill Hospital), Anne‐Sophie Van Rompuy, D. Timmerman(Rega Institute for Medical Research), Ignace Vergote(KU Leuven), Godelieve Verbist(Organ Recovery Systems (Belgium)), Thaïs Baert(Kliniken Essen-Mitte)
Cited by 0
Related Papers
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
|Annals of Oncology|2019|1.2k
Anastrozole Versus Tamoxifen as First-Line Therapy for Advanced Breast Cancer in 668 Postmenopausal Women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability Study
|Journal of Clinical Oncology|2000|840
Terms, definitions and measurements to describe sonographic features of myometrium and uterine masses: a consensus opinion from the Morphological Uterus Sonographic Assessment (MUSA) group
|Ultrasound in Obstetrics and Gynecology|2015|726